Krebs Biochemicals & Industries Past Earnings Performance
Past criteria checks 0/6
Krebs Biochemicals & Industries has been growing earnings at an average annual rate of 3.3%, while the Pharmaceuticals industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 7.6% per year.
Key information
3.3%
Earnings growth rate
7.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 7.6% |
| Return on equity | n/a |
| Net Margin | -37.1% |
| Next Earnings Update | 11 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Krebs Biochemicals & Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 527 | -196 | 167 | 0 |
| 31 Mar 24 | 504 | -197 | 171 | 0 |
| 31 Dec 23 | 499 | -208 | 178 | 0 |
| 30 Sep 23 | 460 | -214 | 173 | 0 |
| 30 Jun 23 | 521 | -219 | 162 | 0 |
| 31 Mar 23 | 521 | -247 | 165 | 0 |
| 31 Dec 22 | 588 | -291 | 164 | 0 |
| 30 Sep 22 | 715 | -365 | 167 | 0 |
| 30 Jun 22 | 636 | -432 | 157 | 0 |
| 31 Mar 22 | 597 | -445 | 160 | 0 |
| 31 Dec 21 | 554 | -402 | 159 | 0 |
| 30 Sep 21 | 432 | -355 | 156 | 0 |
| 30 Jun 21 | 489 | -311 | 149 | 0 |
| 31 Mar 21 | 527 | -284 | 169 | 0 |
| 31 Dec 20 | 516 | -275 | 168 | 0 |
| 30 Sep 20 | 495 | -266 | 166 | 0 |
| 30 Jun 20 | 403 | -280 | 156 | 0 |
| 31 Mar 20 | 324 | -289 | 160 | 0 |
| 31 Dec 19 | 294 | -279 | 158 | 0 |
| 30 Sep 19 | 332 | -271 | 162 | 0 |
| 30 Jun 19 | 435 | -223 | 153 | 0 |
| 31 Mar 19 | 467 | -200 | 158 | 0 |
| 31 Dec 18 | 441 | -220 | 161 | 0 |
| 30 Sep 18 | 528 | -153 | 165 | 0 |
| 30 Jun 18 | 403 | -170 | 146 | 0 |
| 31 Mar 18 | 327 | -178 | 124 | 0 |
| 31 Dec 17 | 266 | -140 | 92 | 0 |
| 30 Sep 17 | 66 | -190 | 63 | 0 |
| 30 Jun 17 | 39 | -183 | 61 | 0 |
| 31 Mar 17 | 21 | -163 | 67 | 0 |
| 31 Dec 16 | 17 | -184 | 63 | 0 |
| 30 Sep 16 | 17 | -172 | 61 | 0 |
| 30 Jun 16 | 17 | -171 | 57 | 0 |
| 31 Mar 16 | 4 | -166 | 65 | 0 |
| 31 Dec 15 | 2 | -264 | 136 | 0 |
| 30 Sep 15 | 2 | -246 | 131 | 0 |
| 30 Jun 15 | 2 | -211 | 89 | 0 |
| 31 Mar 15 | 0 | -60 | -10 | 0 |
| 31 Dec 14 | 0 | -17 | 2 | 0 |
| 30 Sep 14 | 0 | -24 | 7 | 0 |
| 30 Jun 14 | 0 | -37 | 36 | 0 |
| 31 Mar 14 | 0 | 20 | 48 | 0 |
| 31 Dec 13 | 9 | -17 | 57 | 0 |
Quality Earnings: 524518 is currently unprofitable.
Growing Profit Margin: 524518 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524518 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.3% per year.
Accelerating Growth: Unable to compare 524518's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 524518 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.5%).
Return on Equity
High ROE: 524518's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.